@US_FDA officially adding the Digital Health Advisory Committee, originally established in 10/23, expanding the outside expertise advising the agency - https://t.co/L82QeaSCwW
@US_FDA announces #Oncologic#AdComm to discuss #NDA for imetelstat for injection for treatment of transfusion- dependent anemia for 3/14/24 - still by video conf and not in person - https://t.co/I5nPNZ0Upi
@US_FDA issues guidance - #DTC Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format Final Rule: Q &A - https://t.co/qliFn5dHPe
@US_FDA publishing final guidance for #pharma on benefit-risk assessment for new drug and #biologic products to provide clarity on the issue, including how patient experience factors in - https://t.co/rCp867Tk9Y
@US_FDA#OPDP announced it was going to conduct a new study regarding the role of "adherence" in connection with communicating about a medicine - https://t.co/uRKfw6ZO83
@US_FDA issuing draft guidance - Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products replacing 12/29/17 draft - https://t.co/Q6MXkbEXSu
@US_FDA issuing final guidance - Considerations for the Conduct of Clinical Trials of Medical Products During Major Disruptions Due to Disasters and Public Health Emergencies - https://t.co/gLwytYH9iQ #pharma
@US_FDA issuing final guidance - Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act - https://t.co/fcY5xFJoMC #pharma